Peptide Bioregulators: What the Khavinson Peptides Are and What the Evidence Shows
Short peptides, tissue extracts and organ-named products from one Russian research programme - what each category actually is, and how thin the evidence really is.
The short version
Peptide bioregulators are a family of very short peptides and tissue extracts developed since the 1970s at the St Petersburg Institute of Bioregulation and Gerontology. Each is named after the organ it is marketed for, such as Vilon for the thymus and Cortagen for the cerebral cortex. Almost all the evidence comes from that one research group, published mostly in Russian-language or in-house journals and rarely replicated outside that tradition.
- Nearly 500 PubMed records carry a Khavinson bioregulator author; about two-thirds are Russian-language and only 15 are tagged as clinical trials.
- Three kinds of product share this branding: tissue extracts, synthetic short peptides, and the many organ-named variants sold under each.
- Products are named for the organ they target (thymus, pineal gland, cartilage, cerebral cortex), not for a shared mechanism proven to work the same way in each.
- None of these compounds is FDA-approved; all are sold as research chemicals or unregulated capsule/vial products.
“Bioregulator peptide” is a naming convention covering dozens of compounds, all descended from one Russian research programme. Each is branded for the organ it is sold to support.
This page explains where they come from, what separates one kind from another, and how much independent evidence backs the whole family. Read it before any one compound’s page.
Where these peptides come from
Vladimir Khavinson’s group at the St Petersburg Institute of Bioregulation and Gerontology has published on short peptides and tissue-derived preparations since the 1970s. The group’s own review literature calls this a technology for manufacturing biologically active peptide preparations from extracts of different tissues. Later work synthesised very short peptide sequences by rational design Khavinson 2002 - Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144., in the references below.
That literature sometimes calls the whole family “peptide bioregulators” or “cytomedins”. A 2013 review from the same group frames named products as candidate “geroprotectors”, meaning agents proposed to slow age-related decline. The products include Timalin, Thymogen, Vilon, Epithalamin, Prostatilen, Cortexin and Retinalamin Khavinson 2013 - Khavinson VKh, Kuznik BI, Ryzhak GA. [Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results]. Adv Gerontol. 2013;26(1):20-37., in the references below.
Short peptides, extracts and organ-named variants
Three kinds of product circulate under this branding, and it matters which one a given page is describing:
- Tissue extracts. The earliest products were polypeptide-protein complexes extracted from an animal organ, young calf thymus for instance. The research literature describes them as complex preparations rather than a single defined molecule. Vendors sometimes market these under a separate brand family from the synthetic short peptides below. This page does not vouch for any one company’s trademark, only the underlying extract-versus-synthetic distinction.
- Synthetic short peptides. Later work in the same programme identified specific two-to-four-amino-acid sequences, including Lys-Glu, Ala-Glu-Asp and Ala-Glu-Asp-Gly. They are proposed to reproduce an extract’s activity as a single, chemically defined molecule. Epitalon, Pinealon, Cartalax, Testagen and Vilon, all covered on this site, are this kind of product.
- Organ-named variants. Within either category, individual products are named for the organ or tissue they are marketed to support, not for a shared chemical class. Epitalon and Pinealon are for the pineal gland, and Vilon and Thymalin-family products for the thymus (Thymalin and Thymogen, sold as Thymagen, vs thymulin). Cartalax is for cartilage, and so on for the list below.
The organ in a product’s name describes the marketing target and, in some cases, the tissue an extract was drawn from. It does not by itself mean a clinical benefit in that organ has been demonstrated. Read each compound’s own evidence section for what its studies tested. As the Cartalax and Testagen pages on this site show, the organ named in a product’s branding does not always match the tissue its real studies used.
How much evidence actually exists
This is a real, decades-long research programme with hundreds of published records. It is concentrated almost entirely in one research group. It is published mostly in Russian-language or in-house Russian journals that are hard for an outside reader to obtain and appraise. Only a small fraction is even tagged as clinical research of any kind, and little has been independently replicated by researchers outside that tradition.
That caveat applies to every compound on this hub. Each compound’s own page states what its specific studies found, not this overall count.
The bioregulator peptides on this site
- Epitalon - pineal gland, longevity
- Pinealon - pineal gland, cognition
- Cartalax - marketed for cartilage; its real cell-culture evidence is in kidney cells
- Testagen - marketed for testosterone; its real animal evidence is thyroid and thymus outcomes in birds
- Vilon - thymus, immune support
- Thymalin and Thymagen - a calf-thymus extract and the Glu-Trp dipeptide, compared with thymulin
- Vesugen - vascular system
- Cardiogen - cardiovascular system
- Prostamax - prostate
- Cortagen - cerebral cortex
- Bronchogen - bronchial and respiratory tissue
- Chonluten - bronchial tissue, inflammation
- Livagen - liver
- Ovagen - ovarian tissue
- Crystagen - immune system
- Pancragen - pancreas
Are bioregulator peptides legal?
None of the compounds listed above is FDA-approved for any indication in the United States. All are sold internationally as research chemicals or unregulated capsule and vial products, outside any approved drug supply chain. Identity, purity and actual dose are unverified for any given batch.
Regulatory changes for these compounds and others, as they happen: US peptide regulation tracker.
Related
- Semax and Selank: where that Russian research actually sits - the same evidence caveats, for a different pair of Russian-developed peptides
- Research peptides and the law
Common questions
What are bioregulator peptides?
A family of very short peptides (two to four amino acids) and tissue-derived extracts. They have been developed since the 1970s in Russia by Professor Vladimir Khavinson's group at the St Petersburg Institute of Bioregulation and Gerontology. Each is marketed for a specific organ or tissue, such as the thymus, the pineal gland or cartilage. That is based on the organ its original extract was drawn from, or on the tissue-specific gene expression it is proposed to influence.
What is the difference between the extract and synthetic versions?
The earliest products in this programme were polypeptide-protein complexes extracted from specific organs of young animals. The literature describes them as complex peptide preparations from tissue extracts. Later work identified short synthetic sequences, as few as two to four amino acids, proposed to carry the same organ-specific activity. These are made by chemical synthesis rather than extraction. Vendors sometimes market the two categories under separate brand families. This page describes the underlying distinction, not any one company's trademarks.
Is there real research behind these peptides?
Some. Searching PubMed for the lead researcher's name returns close to 500 records. Roughly two-thirds are in Russian, and only 15 are tagged as clinical trials of any kind. It is a real, decades-long research programme. It is concentrated almost entirely in one group, published mostly in Russian-language or in-house Russian journals, and rarely checked by researchers outside that tradition.
What is the usual dose for a bioregulator peptide?
It varies by compound and is covered on each compound's own page, not here. In general, the short courses common to this family run about 10 to 30 days, taken orally or by injection depending on the product, and repeated every few months. This is reported as current practice from vendor and community dosing guides, not as a dose any trial or regulator has established.
Which peptides are bioregulators?
The best-known are the short synthetic peptides from Vladimir Khavinson's programme: Epitalon, Pinealon, Vilon, Cartalax, Testagen, Cortagen, Livagen and others. Older named products the group's own review lists include Timalin, Epithalamin and Cortexin. Each is named for the organ it is marketed for. The list on this page links to each compound's own evidence.
What's the difference between peptides and bioregulators?
Peptide is a chemical category: any short chain of amino acids, which includes approved drugs such as semaglutide. Bioregulator is a name for one family of very short peptides and tissue extracts from a single Russian research programme, each branded for an organ. It is not a separate chemical class. Every bioregulator is a peptide or peptide extract; most peptides are not bioregulators.
Are peptide bioregulators safe?
No regulator has established their safety. None is FDA-approved, and almost all the research comes from one group, with only 15 PubMed records tagged as clinical trials. They are sold as research chemicals or unregulated capsules and vials, so the identity, purity and dose of any batch are unverified. Each compound's own page states what its studies found on side effects.
References (2 sources)
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.